Hyperkalemia Market Trends
DelveInsight's "Hyperkalemia Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Hyperkalemia Market, historical and forecasted epidemiology, the pipeline insight as well as the Hyperkalemia market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Hyperkalemia market report also covers emerging drugs, current treatment practices, Hyperkalemia market shares of the individual therapies, current and forecasted Hyperkalemia Market Size segmented by seven major markets.
Hyperkalemia is defined as the high potassium level in the blood. Potassium helps in the proper functioning of nerves and muscles, including the heart, but too much potassium in the blood can be dangerous and can cause serious heart problems and sudden death.
In a study conducted by Betts et al. (2018), it was estimated that the annual prevalence of hyperkalemia was 1.57% in 2014, with higher rates observed in patients with chronic kidney disease (CKD), heart failure, diabetes, and hypertension. Among patients with CKD and/or heart failure, the 2014 annual prevalence was 6.35%. Among patients with hyperkalemia, 48.43% had CKD and/or heart failure in 2014. The prevalence of hyperkalemia was higher in patients with more severe CKD, as well as older patients and men.
According to the study conducted by Kashihara et al. (2019) titled “Hyperkalemia in Real-World Patients under Continuous Medical Care in Japan,” hyperkalemia prevalence was 67.9/1,000 and increased in patients with chronic kidney disease (CKD), heart failure, and renin-angiotensin-aldosterone system inhibitor (RAASi) use. The mean age was found to be 72.4±13.0 years, and 55% were men.
It was also found in a study by Kanda et al. (2020) that there is an increased number of hospitalizations in hyperkalemic patients The number of repeat hyperkalemic episodes was the most significant factor associated with long-term health care costs. This data was observed from a Japanese nationwide hospital database. Overall more men (55%) were found to have Hyperkalemia.
Hyperkalemia Market Trends Analysis
The Hyperkalemia market analysis section of the report helps to build a detailed comprehension of the historical, current, and forecasted Hyperkalemia market trends and growth by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
The report gives complete detail of Hyperkalemia market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Hyperkalemia Epidemiology Forecast
The Hyperkalemia epidemiology section covers insights about historical and current Hyperkalemia patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
It helps to recognise the causes of current and forecasted Hyperkalemia Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Hyperkalemia Companies operating in the market include AstraZeneca, Ardelyx, Vifor Pharma, Zeria Pharmaceutical, and many others.
Hyperkalemia Therapies covered in the report include RDX013, ZG-801/Patiromer, Lokelma, Veltassa, and many more.
For more details, visit: Hyperkalemia Market Trends